Clinical Trial Update: Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating dexmedetomidine for agitation associated with bipolar disorder has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation Associated with Bipolar Disorder
• Bipolar Disorder

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Agitation Associated With Bipolar Disorder, Agitation,Psychomotor | Phase 3 | Status: COMPLETED | Results posted: 2023-09-11